A detailed history of Trexquant Investment LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 266,471 shares of REPL stock, worth $3.98 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
266,471
Previous 61,198 335.42%
Holding current value
$3.98 Million
Previous $550,000 430.91%
% of portfolio
0.04%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$8.09 - $11.23 $1.66 Million - $2.31 Million
205,273 Added 335.42%
266,471 $2.92 Million
Q2 2024

Aug 13, 2024

SELL
$5.01 - $9.46 $196,572 - $371,172
-39,236 Reduced 39.07%
61,198 $550,000
Q1 2024

May 14, 2024

BUY
$6.87 - $9.31 $689,981 - $935,040
100,434 New
100,434 $820,000
Q2 2023

Aug 11, 2023

SELL
$15.65 - $24.1 $1.08 Million - $1.66 Million
-68,936 Reduced 73.15%
25,298 $587,000
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $1.08 Million - $1.8 Million
61,937 Added 191.77%
94,234 $1.66 Million
Q4 2022

Feb 13, 2023

BUY
$17.09 - $27.91 $165,311 - $269,973
9,673 Added 42.76%
32,297 $878,000
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $67,579 - $91,621
4,332 Added 23.68%
22,624 $391,000
Q2 2022

Aug 11, 2022

SELL
$13.32 - $19.98 $203,702 - $305,554
-15,293 Reduced 45.54%
18,292 $320,000
Q1 2022

May 13, 2022

BUY
$15.24 - $29.75 $511,835 - $999,153
33,585 New
33,585 $570,000
Q1 2021

May 13, 2021

SELL
$30.22 - $45.57 $296,035 - $446,403
-9,796 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$23.5 - $52.65 $230,206 - $515,759
9,796 New
9,796 $374,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $736M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.